Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis
10.3760/cma.j.issn.1003-9279.2009.06.024
- VernacularTitle:国产阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者的疗效及持久性
- Author:
Pei-Ling DONG
1
;
Dong-Mei WANG
;
Xue-Mei ZHANG
;
Bin ZHANG
;
Hui-Guo DING
;
Jia MIN
;
Xin-Yue CHEN
Author Information
1. 首都医科大学附属北京佑安医院
- Keywords:
Hepatitis B e antigens;
Hepatitis B chronic;
Adefovir dipivoxil
- From:
Chinese Journal of Experimental and Clinical Virology
2009;23(6):473-475
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and durability of generic adefovir dipivoxil(ADV)in patients with HBeAg positive chronic hepatitis.Methods 54 nucleosides-naive patients with HBeAg positive chronic hepatitis were enrolled in this randomized,double-blinded,placebo-controlled,prospective study.38 patients received ADV(10 mg once daily)and the others received placebo.The all the patients were treated with ADV for 96 weeks and were followed up for 12 weeks.Results (1)At week 12,the level of ALT declined significantly in ADV group(135.84 ±10.63 U/L to 58.92 ±4.95 U/L,P<0.001)compared with placebo group(145.56±17.19U/L to 159.50 ± 37.05 U/L)(P<0.001).The HBV-DNA level also declined signiticanfly in adefovir group compared with placebo group(2.51 vs 1.04 log10 copies/ml,P<0.001).(2)The rates of normal ALT,normal of AST and undetectable HBV-DNA at 48 and 96 weeks of therapy wlth ADV were 63.30%,70.50%,87.80%,88.60%,53.06%,54.55%,respectively.(3)There were 17 patients discontinuated ADV after 96 weeks.The follow-up results showed that HBV-DNA became positive again in all these 17 patients and abnormal fiver function developed in 88.24%(15/17)patients.Conclusions Treatment of chronic hepatitis B with genetic ADV was effective and well mlemted,but relapse may develop when treatment was discontinued.
